Navigation Links
A Protein May Help In Weight Loss Treatment

Researchers claim to have discovered a process by which a small protein acts directly within muscles to increase the body's metabolism to burn fat while simultaneously suppressing appetite. // This discovery could potentially become a promising new weight loss treatment.

The new study by a team led by a Canadian researcher, Dr. Greg Steinberg reveals how a small protein acts directly within muscles to increase the body's metabolism to burn fat while at the same time suppressing appetite. The protein is knows as the ciliary neurotrophic factor (CNTF). The Heart and Stroke Foundation of Canada, the Canadian Institutes of Health Research, and the Canadian Diabetes Association are funding the research.

They believe that the protein activates an enzyme, skeletal muscle AMP kinase, which increases the ability of the body to metabolise fat and sugar. This study they hope may lead to new strategies to reduce the risk of metabolic abnormalities associated with excess weight.

Steinberg's research shows how CNTF activates similar pathways to those stimulated by exercise. He said that earlier most obesity research has focused on the regulation of appetite by hormones such as leptin. But it is now found that leptin is ineffective in obesity due to the presence of proteins which inhibit their ability to stimulate fat metabolism, he said. He explained that fortunately, CNTF's effects on fat burning are being maintained.

Dr. Diane Finegood, scientific director of the Canadian Institutes of Health Research Institute of Nutrition, stated, this research is an important step for unravelling the complex biological systems controlling body weight, including mechanisms regulating blood sugar levels, food intake, and satiety meaning the feeling of fullness which are crucial to tackling the worldwide epidemic of obesity.

Researchers are working on the pill. But health experts feel it's still a long shot. Actually though Dr.Steinberg is not the first to come to this conclusion, an American pharmaceutical company Regeneron already owns the rights to recombinant CNTF and had completed phase 3 clinical trials of its CNTF medication Axokine. But the trails were discontinued when patients developed antibodies to CNTF that neutralized the effect of the drug.


'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Hamden, CT (PRWEB) , ... December 07, 2016 , ... ... has prompted an outpouring of comments on social media that offer a rare glimpse ... adult psychiatrist, leading ADHD authority and New York Times bestselling author, has described people ...
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... VILLAGE, Calif. , Dec. 6, 2016 ... privately held, clinical-stage medical dermatology and aesthetics ... plc, a privately held specialty pharmaceutical company ... common inflammatory skin conditions, including psoriasis, atopic ... of the agreement, Sienna will make an ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
Breaking Medicine Technology: